[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transient-ischemic-attack-tia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transient-ischemic-attack-tia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,81,120,150,177,201,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100588606","pharmacogenomics-in-stroke-feasibility-of-cyp2c19-testing-100588606",false,"NCT06943586","Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)","CYP-FAST","Inclusion Criteria:\n\n* Patients 18-89 years of age\n* admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA\n* eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)\n\nExclusion Criteria:\n\n* diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)\n* prescribed anticoagulation prior to stroke\n* treated with intravenous thrombolysis\n* treated with mechanical thrombectomy\n* missing NIH Stroke Scale score","ALL","18 Years","89 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.",[28,29],"Stroke","Transient Ischemic Attack (TIA)",[31,32,33,34,35],"Personalized medicine","CYP2C19","minor stroke","Transient Ischemic Attack","TIA","RECRUITING","2026-04-20",{"date":39,"type":40},"2026-04-23","ACTUAL",{"date":42,"type":40},"2025-04-09",{"date":44,"type":22},"2029-04-01",{"name":46,"class":47},"University of Alabama at Birmingham","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100632298","digital-application-for-stroke-health-100632298","NCT07511868","Digital Application for Stroke Health","Evaluating a Digital Health Application for Post-stroke Care and Vascular Risk Factor Management - a Multicenter Randomized Controlled Clinical Investigation","DASH","Inclusion Criteria:\n\n1. Male or female patient (biological sex) ≥18 years at the time of consent\n2. Hospitalization for acute ischemic stroke, acute haemorrhagic stroke or TIA\n3. Necessary Technical Equipment (smartphone or tablet computer) and skills\n4. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Cerebral infarction due to cerebral venous thrombosis (CVT)\n2. Severe Psychiatric Conditions\n3. Severe pre-existing cognitive impairment\n4. Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) or other patients where salt restriction is harmful.\n5. Inability to operate the device independently (assistance from a caregiver is acceptable). E.g.:\n\n   * Severe apraxia,\n   * Severe Motor Disabilities,\n   * Severe Visual Impairment\n   * Severe Communication Barriers (e.g. Severe Aphasia, Severe Dysarthria)\n6. Inability to speak and read German to a level which allows fully comprehending the meaning of everything that is said and written.\n7. Women of childbearing potential not willing to adopt effective contraceptive measures during the clinical investigation\n8. Patients who are considered to be part of the vulnerable population:\n\n   * Persons unable to give consent\n   * Minors\n   * Persons performing military service\n   * persons detained by court or official order or accommodated in accordance with the Accommodation Act, Federal Law Gazette No. 155\u002F1990\n   * Pregnant or breastfeeding women",{"count":58,"type":22},500,[25],"Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge. This study evaluates the effectiveness of a digital health application (StrokeApp) designed to support patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) in secondary prevention and recovery.\n\nIn this multicenter, randomized, controlled, open-label trial, 500 patients will be assigned in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The primary objective is to assess the impact of the application on health-related quality of life three months after discharge. Secondary and exploratory outcomes include health literacy, medication adherence, vascular risk factors, health-related behaviors, psychosocial outcomes, long-term recovery up to twelve months, as well as safety and user experience.",[62,63,29],"Haemorrhagic Stroke","Ischaemic Stroke",[65,66,67,68,69],"Digital Health Application","Post Stroke","Medical Device","App","stroke aftercare","NOT_YET_RECRUITING","2026-03-30",{"date":73,"type":40},"2026-04-06",{"date":75,"type":22},"2026-04-01",{"date":77,"type":22},"2026-12-31",{"name":79,"class":47},"VASCage GmbH",7,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":118,"locationsCount":48},"100625264","ambulatory-stroke-unit-treatment-for-elderly-patients-100625264","NCT07420374","Ambulatory Stroke Unit Treatment for Elderly Patients","Ambulatory Stroke Unit Treatment for Elderly Patients: A Prospective, Randomized, Controlled, Exploratory Non-Inferiority Trial (ARTIFICE)","ARTIFICE","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Diagnosis of acute ischemic stroke (ICD-10 I63.), transient ischemic attack (G45.), or retinal ischemia (H34.\\*)\n* Symptom onset ≤ 7 days before enrollment\n* No or non-disabling newly occurring neurological deficit allowing safe ambulatory management\n* Written informed consent provided by the participant or, if lacking decision-making capacity, by a legally authorized representative\n\nExclusion Criteria:\n\n* Requirement for urgent surgical or interventional secondary prevention (e.g., carotid revascularization)\n* Fluctuating stroke symptoms within the previous 48 hours\n* Acute febrile infection or isolation-requiring infectious disease\n* Clinically relevant dysphagia with high aspiration risk\n* Critical medical or nursing findings requiring mandatory multi-day inpatient treatment\n* Palliative care situation with limitation of acute diagnostic or therapeutic measures\n* Previous participation in the ambulatory stroke unit care model\n* No statutory health insurance coverage in Germany\n* Insufficient German language proficiency to understand study procedures and assessments","60 Years",{"count":91,"type":22},400,[25],"ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits.\n\nEligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design).\n\nSecondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.",[95,29,96],"Ischemic Stroke","Retinal Ischemia",[98,99,100,34,101,102,103,104,105,106,107,108,109,110,111],"Ambulatory Stroke Unit","Stroke Unit Care","Minor Stroke","Geriatric Stroke","Non-Inferiority Trial","Health Services Research","Care Delivery Model","Integrated Stroke Care","Post-Stroke Outcome","Modified Rankin Scale","Quality of Life","Cost-Effectiveness","Stroke Recurrence","Delirium","2026-03-25",{"date":114,"type":40},"2026-03-31",{"date":112,"type":40},{"date":117,"type":22},"2028-12",{"name":119,"class":47},"University Hospital Heidelberg",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100622197","comparing-two-pfo-closure-devices-in-adults-with-previous-stroke-or-tia-100622197","NCT07380490","Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA","Randomised Controlled Trial Comparing the Safety and EfficAcy of the Cocoon PFO Occluder Versus Amplatzer PFO ClosurE Device for Percutaneous Closure of Patent Foramen Ovale in Patients With a History of Stroke or Transient Ischemic Attack A Non-Profit, Single-blind, Investigator Driven Trial","SAFE-PFO","Inclusion Criteria:\n\n* Patients with \\>18 years of age and \\\u003C65 years of age, regardless of gender\n* Patients with normal or aneurysm type PFO confirmed by imaging examination \\[Transthoracic Echocardiography (TTE)\u002F Transesophageal Echocardiography (TOE) or Intracardiac Echocardiography\\], and who exhibit spontaneous right-to-left shunting or right-to-left shunting during Valsalva maneuver.\n* Patients with history of cryptogenic embolic stroke or transient ischemic attack in the previous 12 months \\[stroke is defined as acute focal neurological deficit presumed to be due to focal ischemia, and either 1) symptoms persisting 24 hours or greater, or 2) symptoms persisting less than 24 hours but associated with MR or CT findings of a new, neuroanatomically relevant, cerebral infarct. Transient Ischemic Attack is defined as acute focal neurological deficit (defined as focal motor deficit, aphasia, difficulty walking, hemisensory deficit, amaurosis fugax, blindness, or focal visual deficit) presumed due to focal ischemia, lasting between 5 minutes and 24 hours, that is not associated with MR or CT findings of a new cerebral infarct\\]. The diagnosis of cryptogenic embolic stroke or TIA has to be confirmed by a neurologist.\n* The size of PFO must be amenable to selection of a Cocoon PFO Occluder or Amplatzer PFO closure device.\n* Patients are informed of the nature of the trial and agree to all requirements for participation in the trial, signed the informed consent form, and agreed to complete the follow-up and follow-up examination\n\nExclusion Criteria:\n\n* Patients who have definite causes of stroke or transient ischemic attack unrelated to the PFO\n* RLS caused by other causes, such as atrial septal defect or pulmonary arteriovenous shunt\n* Patients with atrial fibrillation\u002Fatrial flutter (chronic or intermittent) Intracardiac thrombus or tumor\n* Patients with mitral or aortic valve stenosis or severe regurgitation\n* Mitral or aortic valve vegetation or prosthesis\n* Active endocarditis or other untreated infectious diseases\n* Dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy\n* Left ventricular ejection fraction (LVEF) \\\u003C35%\n* Left ventricular aneurysm or akinesis Myocardial infarction or unstable angina pectoris within 12 months\n* Previous intracardiac surgery or percutaneous PFO-closure\n* Atherosclerosis or arteriopathy of intra- or extracranial vessels with \\>50% diameter stenosis in the artery supplying the infarcted territory.\n* Patients with non-embolic cryptogenic stroke (for example lacunar stroke) or with other identifiable causes of stroke, including but not limited to aortic arch plaques (protruding \\>4 mm into the lumen), large artery atherosclerotic disease, an established cardioembolic source, small-vessel occlusive disease, or arterial dissection\n* Glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2 or with any history of renal dialysis or renal transplantation\n* Severe liver function impairment (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal value）\n* Severe pulmonary disease including pulmonary hypertension (clinical diagnosis)\n* Uncontrollable hypertension or diabetes mellitus\n* Contraindications to anticoagulants or antiplatelet drugs, either before or after the PFO closure procedure\n* Active or planned (within 12 months) pregnancy, or lactating female patients\n* Patients with hypercoagulable states\n* Patients diagnosed with a neurological disease that causes progressive neurological dysfunction\n* Malignant tumors or other serious diseases resulting in a life expectancy of less than 12 months\n* Anatomy in which the device would interfere with intracardiac or vascular structures\n* Psychiatric conditions that may interfere with medical compliance and compliance with follow-up\n* Patient is currently participating in another investigational drug or device study that has not reached its primary endpoint yet\n* Patient with any medical condition that would make him\u002Fher inappropriate for treatment as per the current IFU of respective devices or in the opinion of the Investigator\n* Inability to obtain Informed Consent from patient or legally authorized representatives\n* Stroke with poor outcome at time of enrollment (Modified Rankin score \\>3)\n* Subjects who will not be available for follow up for the duration of the trial","65 Years",{"count":130,"type":22},1260,[25],"This study is a prospective, multicenter, randomized, controlled, single-blind, investigator-driven, non-profit clinical trial designed to compare the safety and efficacy of the Cocoon PFO Occluder with the Amplatzer PFO Occluder family in patients requiring percutaneous closure of a patent foramen ovale (PFO). Eligible participants are adults with a history of cryptogenic embolic stroke or neurologically confirmed transient ischemic attack (TIA) within the previous 12 months and a PFO suitable for transcatheter closure.\n\nA total of up to 1260 subjects will be enrolled across multiple European centers. Participants will be randomly assigned in a 3:1 ratio to receive either the Cocoon PFO Occluder (experimental group) or an Amplatzer PFO closure device (control group). The procedure will be performed as soon as possible after randomization, preferably within 14 days and no later than 45 days.\n\nThe primary endpoint is a non-inferiority comparison of a composite outcome at 12 months, including recurrent ischemic stroke, TIA, or all-cause death. Secondary endpoints include PFO closure rate at 6 months, assessed by echocardiographic imaging, and other measures of safety, device performance, and clinical outcomes.\n\nThe study is conducted in a single-blind fashion: patients will not be informed of the device they receive unless they explicitly request this information. Any patient who chooses to be unblinded will continue to participate without affecting eligibility or follow-up, and the date of unblinding will be documented to allow appropriate sensitivity analyses.\n\nThis trial aims to provide robust comparative evidence on the clinical performance of the Cocoon PFO Occluder relative to the Amplatzer PFO Occluder to guide optimal device selection in patients with cryptogenic stroke or TIA associated with PFO.",[134,28,29],"Patent Foramen Ovale",[136,137,138,134,139,34],"PFO Closure","Cocoon PFO Occluder","Amplatzer PFO Occluder","Cryptogenic Stroke","2026-03-23",{"date":142,"type":40},"2026-03-24",{"date":144,"type":22},"2026-04",{"date":146,"type":22},"2028-04",{"name":148,"class":149},"Giuseppe Tarantini","INDUSTRY",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100576265","secondary-prevention-of-ischemic-stroke-and-transient-ischemic-attack-with-an-intelligent-management-system-100576265","NCT06783049","Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System","Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent System","SPIRIT","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients diagnosed with acute ischemic stroke or transient ischemic attack.\n3. Time from onset to enrollment ≤ 14 days.\n4. Presence of at least one modifiable risk factor (hypertension, diabetes).\n5. Ability to independently use a smartphone to complete system tasks upon discharge, or with the assistance of family members.\n6. Signed informed consent by the patient or their family members.\n\nExclusion Criteria:\n\n1. Patients already enrolled in other stroke-related healthcare quality improvement projects or clinical trials.\n2. Patients or family members who refuse to sign the informed consent form.\n3. Pregnant or breastfeeding women.",{"count":159,"type":22},4490,[25],"The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value.\n\nParticipants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group).\n\nAt one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.",[95,29],[164,165,166],"ischemic stroke","secondary prevention","digital health","2026-01-20",{"date":169,"type":40},"2026-01-21",{"date":171,"type":40},"2025-03-03",{"date":173,"type":22},"2027-01-31",{"name":175,"class":47},"Beijing Tiantan Hospital",3,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":48},"100603948","effect-of-the-intelligent-lipid-management-decision-support-system-on-1-year-ldl-c-target-achievement-in-ischemic-stroke-or-tia-patients-under-evolocumab-treatment-in-china-100603948","NCT07143149","Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China","Inclusion Criteria\n\n1. Age≥18 years as of the screening date;\n2. Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;\n3. Prescribed Evolocumab at physician's discretion;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.;\n2. Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis);\n3. Silent cerebral infarction without signs and symptoms;\n4. Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date;\n5. Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date;\n6. Life expectancy \\\u003C12 months or unable to complete the research for other reasons as of the screening date;\n7. Inability to understand and\u002For follow research procedures due to mental, cognitive, or emotional disorders;\n8. Refusal to participate in the enrollment survey.",{"count":184,"type":22},4000,[25],"This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\\\u003C1.8 mmol\u002FL) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.",[95,29],[164,189,190,191,192],"LDL-C","LDL-C Target Achievement","the Intelligent Lipid Management Decision-support System","Evolocumab","2025-12-29",{"date":195,"type":40},"2026-01-02",{"date":197,"type":40},"2025-11-03",{"date":199,"type":22},"2028-03-31",{"name":175,"class":47},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":48},"100571271","canadian-tia-score-versus-abcd2-score-in-risk-stratification-of-transient-ischemic-attack-tia-100571271","NCT06718075","Canadian TIA Score Versus ABCD2 Score in Risk Stratification of Transient Ischemic Attack (TIA)","Inclusion Criteria:\n\n* all patients presenting to the emergency department with a diagnosis of TIA\n* all adult patients\n* all patients who have signed the informed consent\n\nExclusion Criteria:\n\n* none",{"count":208,"type":22},800,"OBSERVATIONAL","This study aims to evaluate the superiority of a clinical score (Canadian TIA score) compared to the currently more widely used score in clinical practice (ABCD2 score) in stratifying the risk of stroke or carotid revascularization following a transient ischemic attack at 7 days, and to assess its superiority at 90 days in a European population.\n\nPatients with transient ischemic attack are at high risk of developing a subsequent stroke, especially in the short term. Identifying patients at greater risk would allow for optimized management to provide aggressive treatment within the first days following the event. All patients attending the Emergency Medicine department of this hospital will be enrolled over a consecutive 24-month period. Approximately 800 participants are expected to take part in this study.\n\nAt the time of admission to the Emergency Medicine department, the various prognostic scores relevant to the study will be completed, taking about one minute. At 7 and 90 days from the date of admission, the patient will be contacted by phone and will be administered a validated questionnaire (Questionnaire for Verifying Stroke-Free Status), which will take approximately one minute.",[29],"2024-12-01",{"date":214,"type":40},"2024-12-05",{"date":216,"type":40},"2022-09-01",{"date":218,"type":22},"2025-08-31",{"name":220,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":232,"studyType":209,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":48},"100278144","population-based-brest-stroke-registry-100278144","NCT02900521","Population-based Brest Stroke Registry","The Brest Registry of Stroke","BREST","Inclusion Criteria:\n\n* Diagnostic validated for one of the following pathologies:\n* Ischemic stroke,\n* Non-traumatic intracranial hematoma\n* Cerebral venous thrombosis Diagnostic after December 31, 2007 Age \\> 15 years on the date of the diagnostic Patient domiciled at the time of the diagnostic in one of the 79 communes defined beforehand\n\nExclusion Criteria:\n\n* Age ≤ 15 years\n* Validated diagnosis (see below, § 4.2.2) of aneurysmal subarachnoid hemorrhage cerebrovascular\n* Diagnosis made before 1 January 2008\n* Unconfirmed diagnosis\n* Patient domiciled outside the previously defined area of residence","15 Years",{"count":231,"type":22},15000,"10 Years","The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.",[235,236,28,237,238,95,239,240,29],"Cerebral (CVAs)","Ischemic Cerebrovascular Accident","Brain Ischemia","Brain Hemorrhage","Hemorrhagic Stroke","Cerebrovascular Disorders","2023-05-25",{"date":243,"type":40},"2023-05-26",{"date":245,"type":40},"2008-01",{"date":247,"type":22},"2026-12",{"name":249,"class":47},"University Hospital, Brest"]